Shareholder presentation shared at 41st AGM covering FY 2025-26 milestones
The company shared with the exchanges the presentation made to shareholders at its 41st Annual General Meeting held on September 26, 2026, covering FY 2025-26.
- Sayakha methylamines facility
- Commissioned and ramped up in 2026, strengthening backward integration for Metformin portfolio
- USFDA approval
- Received for the oncology facility in 2026
- UK MHRA approval
- Received for the oral solid dosage (OSD) facility in 2026
- EU GMP certifications
- Received for the oncology and general capsule lines in 2026
- Consolidated turnover milestone
- Crossed Rs. 2,500 crores in 2022
What was shared
Aarti Drugs Limited submitted to BSE and NSE the presentation made to shareholders at its 41st Annual General Meeting held on September 26, 2026. The deck relates to FY 2025-26 and opens with a company and business overview.
Recent milestones highlighted for 2026
- Commissioned and ramped up the Sayakha methylamines facility, strengthening backward integration for the Metformin portfolio.
- Received USFDA approval for the oncology facility and UK MHRA approval for the oral solid dosage (OSD) facility.
- Received EU GMP certifications for the oncology and general capsule lines.
Earlier landmarks in the journey
- 1984: Incorporation; 1993: listed on BSE; 2003: listed on NSE.
- 1996: merger of several group entities into a more integrated organisation.
- 2008: one facility approved by the USFDA.
- 2014: crossed Rs. 1,000 crores turnover and expanded into formulations through 100% subsidiary Pinnacle Life Science Private Limited.
- 2021: surpassed consolidated turnover of Rs. 2,000 Crores, Pinnacle Life Science crossed Rs. 200 Crores turnover, and Profit After Tax surpassed Rs. 200 Crores.
- 2022: crossed Rs. 2,500 crores consolidated turnover.
- 2024: entered the personal care segment with a greenfield dermatology project at Tarapur.
How to read this
An AGM presentation is an information document rather than a new business decision. It sets out how management describes the company's scale, regulatory approvals and capacity additions. Backward integration at Sayakha relates to in-house supply of a key input for Metformin, while the USFDA, MHRA and EU GMP clearances relate to the ability to supply regulated markets. The deck itself carries a safe harbour note stating that forward-looking statements are not guarantees of future performance.
Also from Aarti Drugs
Authorized persons for determining materiality and making disclosures to exchanges named from October 1, 2026
1 Oct 2026
Chairman, MD & CEO Prakash M. Patil retires early; Adhish P. Patil promoted to MD, steps down as CFO
30 Sep 2026
More numbers
- Consolidated turnover crossed (2022)Rs. 2,500 crores
- Consolidated turnover surpassed (2021)Rs. 2,000 Crores
- Turnover crossed (2014)Rs. 1,000 crores
- Pinnacle Life Science turnover surpassed (2021)Rs. 200 Crores
- Profit After Tax surpassed (2021)Rs. 200 Crores
- Holding in Pinnacle Life Science Private Limited100%
- Annual General Meeting number41st
Nothing here is a view, opinion or recommendation of ScoutQuest, its parent, directors or employees. ScoutQuest is a technology company: this page was assembled automatically from public sources using artificial intelligence, and may contain errors or omissions. Confirm everything against the original source before you act on it. Any use of this page is at your own risk, and neither ScoutQuest nor its parent, directors or employees accepts liability for it.